{
    "root": "60b67c0d-2c60-400a-9ff6-2dad158a4ee7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250228",
    "ingredients": [
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X"
        },
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM CARBONATE DECAHYDRATE",
            "code": "LS505BG22I"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "pantoprazole proton pump inhibitor ( ppi ) indicated following : \u2022 short-term treatment erosive esophagitis associated gastroesophageal reflux disease ( gerd ) ( 1.1 ) \u2022 maintenance healing erosive esophagitis ( 1.2 ) \u2022 pathological hypersecretory conditions including zollinger-ellison ( ze ) syndrome ( 1.3 )",
    "contraindications": "indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 wks children ( 5 years older ) \u2265 15 kg < 40 kg 20 mg daily 8 wks \u2265 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily * pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily * controlled extend beyond 12 months full prescribing information instructions",
    "warningsAndPrecautions": "supplied pantoprazole sodium delayed-release tablets , usp supplied 40 mg white pale yellow colored , oval shape , biconvex , enteric-coated tablets , plain one side `` 97 `` printed brown ink side . available follows : overbagged 10 delayed-release tablets per bag , ndc 55154-7634-0 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022pantoprazole sodium contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . \u2022proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole is a proton pump inhibitor (PPI) indicated for the following: \u2022 Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) \u2022 Maintenance of Healing of Erosive Esophagitis ( 1.2 ) \u2022 Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) \u00a0Syndrome ( 1.3 )",
    "contraindications_original": "Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) \u2265 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks \u2265 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily * Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  Pantoprazole sodium delayed-release tablets, USP are supplied as 40 mg white to pale yellow colored, oval shape, biconvex, enteric-coated tablets, plain on one side and \"97\" printed with brown ink on the other side.\n                  They are available as follows:\n                  Overbagged with 10 delayed-release tablets per bag, NDC 55154-7634-0\n                  \n                     Storage\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6)].\n                     \n                        \u2022Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}